Media Centre
News
Media Relations
Publications and Magazines
JGH TV
Contact Us

News from the JGH 
 
Back to full list
2018/09/25
Promising novel treatment against Alzheimer Disease

 

 

Research conducted at the Lady Davis Institute provides proof of concept that an existing drug holds promise for reversing loss of memory and brain lesions associated with Alzheimer disease.

September 25, 2018, Montreal – New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.

For years, Dr. LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss. Her team discovered that the Caspase-6 enzyme is highly activated in Alzheimer disease brain lesions and associated with loss of memory. She, therefore, pursued the hypothesis that stopping Caspase-6 might provide relief from memory loss and stop progressive dementia. Since there are no specific Caspase-6 inhibitors, the LeBlanc team moved upstream, ultimately discovering that Caspase-1 was responsible for activating Caspase-6.

“This was a significant revelation because Caspase-1 inhibitors had been developed for treating inflammatory diseases,” explains Dr. LeBlanc. “Thus, we decided to test the effects of a particular Caspase-1 inhibitor, called VX-765, against memory loss and brain pathologies in a mouse model of Alzheimer disease.”

The work, first authored by Dr. Joseph Flores, a research associate in the LeBlanc lab, showed that VX-765 has an unprecedented beneficial effect in Alzheimer mice. The drug rapidly reverses memory loss, eliminates inflammation, and stops Alzheimer’s prototypical amyloid peptide accumulation in the mice brains. In addition to being safe for humans at relatively high doses for extended periods of time, it is capable of reaching the brain, a significant challenge in the development of drugs against disorders of the brain.

While Dr. LeBlanc cautions that there is a considerable bridge to cross between the mouse brain and that of a human, she believes that since her work has first identified the Caspase-1/Caspase- 6 neurodegenerative pathway in human neurons and in human Alzheimer brains, there is a chance that this drug will work just as well in humans as it did in mice. Nevertheless, a clinical trial is needed to determine whether the drug will be beneficial against Alzheimer disease in humans.

Presently, there are no efficient treatments to significantly treat Alzheimer disease, the major affliction in a group of dementias that affect 47.5 million individuals worldwide.

Dr. LeBlanc’s work has benefited from the generous support of the JGH Foundation, the Canadian Institutes of Health Research, the National Institutes of Health, and the Alzheimer’s Society of Canada.


Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model, Joseph Flores, Anastasia Noël, Bénédicte Foveau, Jeffrey Lynham, Clotilde Lecrux & Andréa C. LeBlanc, Nature Communications.

For media inquiries, and to arrange interviews with Dr. LeBlanc contact:

Carl Thériault

Relations médias et affaires politiques | Media and Political Relations
Hôpital général juif | Jewish General Hospital
CIUSSS du Centre-Ouest-de-l'Ile-de-Montréal | West Central Montreal Health
T: 514-340-8222 # 28424 | 514 618-5430 (urgences médias)
carl.theriault.CCOMTL@ssss.gouv.qc.ca

For more about the Lady Davis Institute: www.ladydavis.ca

For more about the Jewish General Hospital: www.jgh.ca